Gossamer Bio, Inc.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing seralutinib, an inhaled therapy candidate for pulmonary arterial hypertension and related cardiopulmonary diseases. The company currently has no product sales and is funded primarily through collaboration revenue, equity financing, and other capital sources while it advances development and prepares for potential commercialization.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical and preclinical development of seralutinib, the company's lead inhaled therapy candidate.
Cost reimbursement and cost-sharing payments from the Chiesi collaboration.
Upfront, regulatory, commercial milestone, and royalty economics tied to the Chiesi partnership.
Potential direct sales of seralutinib if regulatory approval and commercialization are achieved.
Tuotteet
Raportoitu · osuus liikevaihdosta- License and Service79,1 %
- Revenue From Contracts with Collaborators20,9 %
Lähde: 10-K FY2024, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Gossamer Bio does not currently sell approved products to end customers; its current revenue comes from Chiesi under a global collaboration. If seralutinib is approved, the company would serve patients with pulmonary arterial hypertension and other cardiopulmonary diseases through physicians, hospitals, and specialty pharmacies, with commercialization split across the U.S. and ex-U.S. territories.
Chiesi funds shared development and commercialization economics under the global seralutinib agreement.
Future patients who may receive seralutinib if it is approved for PAH and related indications.
Pulmonologists, cardiologists, and specialty centers that would prescribe and monitor therapy.
Insurers, government programs, and HTA bodies that determine access and pricing after approval.
Strategia
The company's near-term strategy is to advance seralutinib through Phase 3 development while managing cash burn and preserving optionality for future commercialization. The Chiesi partnership is central to this plan because it shares development costs, provides non-dilutive funding, and creates a pathway to global launch if the asset succeeds.
Clinical success is the main value driver and prerequisite for approval and commercialization.
The partnership reduces funding needs and shares commercialization risk.
The company has no product revenue and may need additional capital before approval.
Approval would require manufacturing, distribution, and market access capabilities.
Maantiede
The company is headquartered in the United States and its current operations are centered on U.S.-based clinical development and corporate functions. Through the Chiesi agreement, seralutinib has worldwide development and commercialization rights, creating exposure to U.S. and ex-U.S. regulatory, pricing, and reimbursement regimes.
Riskit
Gossamer Bio is exposed to clinical, regulatory, and financing risk because its value depends heavily on a single lead asset that is still in development. Future commercialization also depends on payer access, pricing pressure, and cross-border regulatory frameworks, while the company may need to raise additional capital before it can generate meaningful product revenue.
- Clinical development failure for seralutinibVaikutus: KriittinenTodennäköisyys: Korkea
The company has no approved products and depends on one lead candidate for future value creation.
Kohdistuu: Phase 3 and regulatory pathway
- Financing and liquidity riskVaikutus: KorkeaTodennäköisyys: Korkea
Current revenue is collaboration-based and may not support the cost structure before approval.
Kohdistuu - Pricing and reimbursement pressureVaikutus: KorkeaTodennäköisyys: Matala
State drug pricing rules, hospital bidding, and payer controls can reduce net realized pricing.
Kohdistuu: U.S. and ex-U.S. commercialization
- Regulatory and HTA delaysVaikutus: KeskitasoTodennäköisyys: Kohtalainen
EU HTA and national reimbursement decisions can delay or constrain market access.
Kohdistuu: Europe commercialization
- Trade and supply chain disruptionVaikutus: Keskitaso
Tariffs, export controls, and import/export changes can affect development and commercialization logistics.
Kohdistuu: Global supply chain and manufacturing
Kirjanpito
Harkinnanvaraiset erätRevenue includes a one-time license reimbursement and ongoing service reimbursements, which affects timing and comparability.
Vaikutus: Can create large period-to-period swings in reported revenue
R&D costs are driven by trial progress, enrollment, and manufacturing activity.
Vaikutus: Directly affects operating loss and cash burn
Acquired or in-licensed IPR&D with no alternative future use is expensed immediately.
Vaikutus: Can create one-time operating expense spikes
A meaningful portion of employee compensation is equity-based in R&D and G&A.
Vaikutus: Affects operating expenses and non-cash dilution
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Seres Therapeutics, Inc.
MCRB · Pharmaceutical Preparations
Serina Therapeutics, Inc.
SER · Pharmaceutical Preparations
Tenax Therapeutics, Inc
TENX · Pharmaceutical Preparations
Upstream Bio, Inc.
UPB · Pharmaceutical Preparations
Cogent Biosciences, Inc.
COGT · Pharmaceutical Preparations
Rezolute, Inc.
RZLT · Pharmaceutical Preparations
Päivitetty: 24.9.2026